• Home The epothilones and taxanes are the anti-cancer drug Taxol already in use.

The epothilones and taxanes are the anti-cancer drug Taxol already in use.

– The epothilones and taxanes are the anti-cancer drug Taxol already in use, the researchers have now investigated two drug candidates families. Both drugs work division of cancer cells division of cancer cells by binding to the same site on a protein called tubulin, Tubulin cell division. Tubulin is the major component of microtubules, the hollow cylinder, which serve as a skeletal system for cells and scaffold for chromosomes in dividing cell. When epothilones or taxanes tubulin tubulin, the protein loses its flexibility and the microtubules disassemble no longer to stop cell division.

The discovery potentially opens the door for the creation of more effective cancer treatments. The detection and mapping the structure of this model system will around the world around the world in creating new connections that lead hopefully to new cancer drugs, says researcher Jim Snyder, a chemist and director of Emory University biostructural.

The results, in the sixth August issue of the journal Science reported, the first three – dimensional, atomic-scale images of the binding site, where one of the drugs, epothilone A, interacts with an important protein controlling cell division.

This means are called non – between doses of man-made sources of ionizing radiation and to make from natural sourcesFinally, it is important to know that the radiation in the environment that come from sunlight, power lines, electrical appliances and mobile communications is not enough energy to produce this ionizations.To further help you to determine the measures of the measures to deal, AF Stat loads anybody affected by or are interested AFib go go to recommended priority action belong.

Enhance Specify best practice across AFib Owners, orient improving clinical practice and implementation power measures for treatment results – Holiday. ‘In the past was is a disappointing want of urgency of the status quo the status quo the surrounding AFib,’said Eric Prystowsky, AF Stat Medical Chair and Director Clinical Electrophysiology Lab, Vincent Hospital in Indianapolis. ‘That Call to Action provides key public health regulations change change and can be to better understand and management of atrial fibrillation.